Back to top
more

Savara (SVRA)

(Real Time Quote from BATS)

$5.91 USD

5.91
677,051

+0.13 (2.25%)

Updated Apr 8, 2026 03:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (94 out of 243)

Industry: Medical - Drugs

Brokerage Reports

Research for SVRA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Savara Inc. [SVRA]

Reports for Purchase

Showing records 1 - 20 ( 63 total )

Company: Savara Inc.

Industry: Medical - Drugs

Record: 1

03/09/2026

Company Report

Pages: 7

Breathing Easier: MOLBREEVI Clears a Key Overhang

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 2

12/23/2025

Company Report

Pages: 7

The Comeback Filing: Savara Resubmits Molbreevi BLA - Raising PT to $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 3

11/13/2025

Company Report

Pages: 7

On Track for BLA Resubmission of Molbreevi; Potential Launch Mid-2026

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 4

09/03/2025

Company Report

Pages: 7

Positive Readthrough on the Increase of Expected aPAP Patient Population; Increase PT to $8

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 5

08/15/2025

Company Report

Pages: 8

Clarity on Tech Transfer and Upcoming BLA Resubmission; Upgrading to Buy, Raising PT to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 6

05/29/2025

Company Report

Pages: 8

Downgrading to Neutral; PT Reduced to $2

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 7

05/14/2025

Company Report

Pages: 7

Sights on Prospective Molbreevi Launch Early 2026 Awaiting Forthcoming Approval; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 8

03/28/2025

Company Report

Pages: 7

Molbreevi BLA Submitted with Prospective YE25 PDUFA?Looking to aPAP Penetration

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 9

11/13/2024

Company Report

Pages: 7

The Race to 1,000 - Our Thoughts on Molbreevi Launch Expectations; Decreasing PT to $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 10

10/08/2024

Daily Note

Pages: 4

You Can Lead A Horse to Water, But You Cannot Make It Drink - KOL''s Thoughts on aPAP Testing at CHEST 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 11

10/01/2024

Company Report

Pages: 7

Our Thoughts on Investor Day Market Opportunity Estimates; Reiterate Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 12

08/14/2024

Company Report

Pages: 7

Molbreevi Paving Path to First Potential aPAP Approval; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 13

06/27/2024

Company Report

Pages: 7

IMPALA-2 Phase 3 Trial Hits Primary Endpoint For Molgramostim -KOL Thoughts on Data; Reit. Buy; Increasing PT to $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 14

05/31/2024

Industry Report

Pages: 5

Views on Clinical Progress in the Respiratory Field

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 15

05/13/2024

Company Report

Pages: 7

Optimistic on Near-Term Topline Molgramostim Data; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 16

03/11/2024

Company Report

Pages: 7

Molgramostim Near-Term Pivotal IMPALA-2 Topline Expected 2Q24; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 17

01/31/2024

Daily Note

Pages: 114

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 18

01/30/2024

Daily Note

Pages: 115

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 19

11/13/2023

Company Report

Pages: 7

Molgramostim Advances With Phase 3 IMPALA-2 Topline Expected 2Q24; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Savara Inc.

Industry: Medical - Drugs

Record: 20

08/14/2023

Company Report

Pages: 7

Molgramostim Pivotal IMPALA-2 Progress-Positioned for Success; PT Up to $6, Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party